Compare Abbott Laboratories (ABT) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Harley-Davidson Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Harley-Davidson Inc trades at $25.32 (market cap $2.73B). The key difference: Abbott Laboratories is far larger — about 61.2× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| ABT | HOG | |
|---|---|---|
Market Cap | $166.94B | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $31.03 |
52-Week Low | $82.57 | $17.19 |
Enterprise Value | $193.69B | $3.12B |
Dividend Yield | 2.63% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Harley-Davidson (HOG) trades at $25.89, up 3.73% today, with mixed technical signals showing bullish moving averages but neutral oscillators. Fundamentally, the company faces revenue declines from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 13.12 and P/B of 0.87. Recent Q1 2026 earnings missed expectations at $0.22 vs. $0.34, but Q2 results are anticipated on July 23, 2026. Positive developments include production returning to the US and cost-cutting initiatives.
The outlook is cautious with analyst consensus at Hold (65.71%) and price target of $23.20 below current price. Risks include ongoing margin pressure, competitive threats, and execution of turnaround plans. Upside potential exists if cost savings and US production boost profitability, but investors should monitor Q2 earnings for confirmation of operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
